Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recent advances in the treatment of epithelial ovarian cancer
Autore:
Harries, M; Kaye, SB;
Indirizzi:
Royal Marsden Hosp, Crc Dept Med Oncol, Sutton SM2 5PT, Surrey, England Royal Marsden Hosp Sutton Surrey England SM2 5PT SM2 5PT, Surrey, England
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 9, volume: 10, anno: 2001,
pagine: 1715 - 1724
SICI:
1354-3784(200109)10:9<1715:RAITTO>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-II TRIAL; PLATINUM-PRETREATED PATIENTS; SINGLE 2ND-LINE AGENT; HIGH-DOSE EPIRUBICIN; REFRACTORY OVARIAN; LIPOSOMAL DOXORUBICIN; STAGE-III; DOCETAXEL TAXOTERE(R); FOLLOW-UP;
Keywords:
altretamine; cisplatin; carboplatin; docetaxel; drug resistance; etoposide; gemcitabine; gene therapy; liposomal doxorubicin; ovarian carcinoma; oxaliplatin; paclitaxel; recurrent ovarian carcinoma; signal transduction inhibitors; tamoxifen; topotecan; vinorelbine;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Harries, M Royal Marsden Hosp, Crc Dept Med Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England Royal Marsden Hosp Downs Rd Sutton Surrey England SM2 5PT gland
Citazione:
M. Harries e S.B. Kaye, "Recent advances in the treatment of epithelial ovarian cancer", EXPERT OP I, 10(9), 2001, pp. 1715-1724

Abstract

Ovarian cancer leads to more fatalities than any other form of gynaecological cancer in North America and Europe. Over the last 30 years survival figures have improved somewhat due to improvements in diagnosis, surgery and chemotherapy. Despite these advances, the majority of patients will die fromtheir disease, with the overall 5-year survival being just 30%. The majority of patients with this disease will require treatment with cytotoxic chemotherapy. It is now well established that the platinum agents (cisplatin orcarboplatin) are the most important drugs to be included in first-line regimens. More recently, randomised trials have confirmed the benefit of the addition of taxanes to platinum-containing regimens and the standard of carehas become the combination of carboplatin and paclitaxel. Several unanswered questions remain regarding the optimal schedule, the optimum duration oftreatment, possible benefits to be gained from the addition of other drugsand whether paclitaxel the best taxane. Despite high response rates to first line chemotherapy, the majority of patients with advanced ovarian cancerwill relapse and will be candidates for further chemotherapy, which can palliate symptoms and improve survival even in recurrent disease. For a patient relapsing within six months of first-line treatment, studies have shown that there is little point in rechallenge with the same drugs. However, forpatients who have a longer treatment-free interval the response rates to rechallenge with platinum is significant. A number of drugs have been shown to have activity in platinum- and taxane-refractory disease and are approved for this and/or other applications. These include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretamine, oxaliplatin and vinorelbine. Anti-oestrogens such as tamoxifen have a small but significant response rate. Recurrent ovarian cancer is a good setting to test investigational agents and compounds with promising activity including new platinums and taxoids, as well as a range of new compounds. Non-cytotoxic approaches that are showing promise include therapies designed to overcome drug resistance, signal transduction inhibitors, immunotherapy and gene therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 07:22:51